DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Inclusion Criteria

• •1. corresponding to the AML (except M3) or high-risk MDS diagnostic criteria, with any of the following circumstances:
• •①secondary AML patients (including AML secondary to MDS)
• •②corresponding to refractory AML diagnostic standard ( relapsed refractory acute myeloid leukemia Chinese guidelines(2017 Edition): Refractory AML diagnostic criteria: invalid after standard treatment 2 cycles of untreated cases; consolidation therapy after CR and then recurrence within 12 months; recurrence after 12 months and then invalid after conventional chemotherapy ; relapse of ≥ 2 times ; extramedullary leukemia continued existence.
• •③corresponding to recurrent AML diagnostic criteria (relapsed refractory acute myeloid leukemia China guidelines (2017 Edition): peripheral blood leukemia cells or bone marrow progenitor cells appear again \> 0.050 after CR (with the exception of bone marrow regeneration after consolidation chemotherapy and other reasons) or leukemia cells infiltration appear in extramedullary
• •④corresponding to MDS refractory anemia with blasts excess (RAEB) diagnosis standards
• •2. Age ≥18 years old
• •3. Eastern Cooperative Oncology Group(ECOG) score 0-3
• •4. Expected survival ≥8 weeks
• •5. Patients must be able to understand and be willing to participate in this study, and signed informed consent